Probiotics in Gastrointestinal Disorders

Probiotics are currently defined by the World Health Organization as "live microorganisms which when administered in adequate amounts confer health benefits on the host." There are trillions of bacteria which live in our digestive tracts. More than 400 different species have been identified. Most of these are healthy bacteria while others have the potential to cause damage to our intestinal systems.

Bacterial microflora of the gastrointestinal (GI) tract may play an important role in the pathophysiology of some GI disorders. Probiotics have been used as a treatment modality for over a century. They may restore normal bacterial microflora and effect the functioning of the GI tract by a variety of mechanisms. Probiotics are not currently regulated and only few randomized controlled trials exist investigating their efficacy in different GI disorders. They are available in a variety of formulations and delivery systems making interpretation and comparison of studies even more difficult. The efficacy of probiotics, either as a single strain or a combination of probiotics, has been tested in antibiotic-associated diarrhea, Clostridium difficile colitis, infectious diarrhea, ulcerative colitis, Crohn’s disease, pouchitis, and irritable bowel syndrome, among other disorders. Many questions regarding use of probiotics in GI disorders remain to be answered in future studies, such as most optimal doses, duration of treatment, physiological and immunological effects, efficacy of specific probiotics in specific disease states, and safety in debilitated patients.

    Related Conference of Probiotics in Gastrointestinal Disorders

    July 25-26, 2024

    3rd International Conference on Gastroenterology and Liver

    Amsterdam, Netherlands
    November 21-22, 2024

    23rd World Congress on Gastrointestinal Cancer

    Dubai, UAE

    Probiotics in Gastrointestinal Disorders Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in